Regeneron Pharmaceuticals has attracted significant
investment activity with numerous entities, such as Novem Group, British Columbia Investment Management Corp, and Royal Bank of Canada, amassing substantial amounts of REGN shareholdings. Renowned investor Jim Cramer lauded the
company's innovative biopharma practices and considers it a smart stock. Regeneron recently announced acquiring
23andMe in a bankruptcy auction, promising ethical use of customer DNA data – a move seen as a strategic edge. On the R&D front, the firm reported encouraging initial outcomes from its
LINKER-MM1 Trial for
Linvoseltamab, a promising drug for multiple myeloma. A partnership with
Viz.ai is set to revolutionize COPD solutions using AI. The company also plans a $7b expansion thanks to surging Dupixent sales. However, a drop was noted in first quarter 2025 revenue and competitors’ growth resulted in the narrowing of margins. Citigroup upgraded Regeneron's rating to ‘Buy’, while a recent lawsuit urges shareholders to get in touch with the Shareholders Foundation.
Regeneron Pharmaceuticals REGN News Analytics from Mon, 10 Mar 2025 07:00:00 GMT to Sat, 24 May 2025 12:17:08 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor -4
